Lataa...
Influenza A and B viruses with reduced baloxavir susceptibility display attenuated in vitro fitness but retain ferret transmissibility
Baloxavir marboxil (BXM) was approved in 2018 for treating influenza A and B virus infections. It is a first-in-class inhibitor targeting the endonuclease activity of the virus polymerase acidic (PA) protein. Clinical trial data revealed that PA amino acid substitutions at residue 38 (I38T/F/M) redu...
Tallennettuna:
| Julkaisussa: | Proc Natl Acad Sci U S A |
|---|---|
| Päätekijät: | , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
National Academy of Sciences
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7165484/ https://ncbi.nlm.nih.gov/pubmed/32217734 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1916825117 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|